Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-21-042110
Filing Date
2021-06-21
Accepted
2021-06-21 17:04:19
Documents
1
Period of Report
2021-06-17

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 3966
  Complete submission text file 0001209191-21-042110.txt   5389
Mailing Address C/O AVEXIS, INC., 2275 HALF DAY ROAD SUITE 160 BANNOCKBURN IL 60015
Business Address
Nagendran Sukumar (Reporting) CIK: 0001665124 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39536 | Film No.: 211031635

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Issuer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)